| 6 -0.24 (-3.85%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.28 |
1-year : | 7.73 |
| Resists | First : | 6.23 |
Second : | 6.61 |
| Pivot price | 6.13  |
|||
| Supports | First : | 5.61 |
Second : | 4.66 |
| MAs | MA(5) : | 6.31 |
MA(20) : | 6.06 |
| MA(100) : | 6.91 |
MA(250) : | 6.12 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.4 |
D(3) : | 71.1 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 9.93 | Low : | 4.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VNDA ] has closed above bottom band by 32.6%. Bollinger Bands are 56.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.27 - 6.31 | 6.31 - 6.33 |
| Low: | 5.88 - 5.93 | 5.93 - 5.96 |
| Close: | 5.94 - 6.01 | 6.01 - 6.06 |
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Sat, 11 Jul 2026
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Fri, 10 Jul 2026
Vanda Pharmaceuticals plans fireside chat at Boston investor summit - Stock Titan
Fri, 10 Jul 2026
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - Yahoo Finance
Thu, 09 Jul 2026
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
Tue, 07 Jul 2026
Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 78.1 (%) |
| Shares Short | 7,340 (K) |
| Shares Short P.Month | 6,810 (K) |
| EPS | -4.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.53 |
| Profit Margin | -110 % |
| Operating Margin | -97.2 % |
| Return on Assets (ttm) | -18.9 % |
| Return on Equity (ttm) | -60.5 % |
| Qtrly Rev. Growth | 3.4 % |
| Gross Profit (p.s.) | 3.41 |
| Sales Per Share | 3.62 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -127 (M) |
| Levered Free Cash Flow | -83 (M) |
| PE Ratio | -1.48 |
| PEG Ratio | 2.2 |
| Price to Book value | 1.08 |
| Price to Sales | 1.65 |
| Price to Cash Flow | -2.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|